Related Experiment Video

Updated: Jul 13, 2026

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells
09:02

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells

Published on: June 5, 2020

Noninvasive models to predict liver cirrhosis in patients with chronic hepatitis B

Beom Kyung Kim1, Sung Ae Kim, Young Nyun Park

  • 1Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.

Liver International : Official Journal of the International Association for the Study of the Liver
|August 19, 2007
PubMed

Insights

The novel Age-Spleen-Platelet Ratio Index (ASPRI) accurately predicts liver cirrhosis in chronic hepatitis B (CHB) patients. This noninvasive screening tool shows potential to reduce the need for liver biopsies.

Area of Science:

  • Hepatology
  • Diagnostic Accuracy
  • Biomarker Development

Background:

  • Noninvasive models for predicting liver cirrhosis in chronic hepatitis B (CHB) are limited.
  • Accurate prediction of cirrhosis is crucial for CHB management and preventing complications.

Purpose of the Study:

  • To evaluate the diagnostic accuracy of two novel noninvasive models: spleen-platelet ratio index (SPRI) and age-spleen-platelet ratio index (ASPRI).
  • To compare SPRI and ASPRI with existing models like aspartate to alanine aminotransferase ratio (AAR), age-platelet index (API), and aspartate aminotransferase to platelet ratio index (APRI) for predicting liver histology in CHB patients.

Main Methods:

  • Retrospective study of 346 treatment-naïve CHB patients.
  • Comparison of AAR, API, APRI, SPRI, and ASPRI against liver histology.
  • Analysis of diagnostic accuracy using receiver operating characteristic (ROC) curves.

Main Results:

  • All five tested models (AAR, APRI, SPRI, API, ASPRI) showed significant correlation with liver fibrosis stage (P<0.001).
  • ASPRI demonstrated the highest diagnostic accuracy for predicting cirrhosis, with an area under the ROC curve (AUROC) of 0.893.
  • ASPRI >12 correctly identified cirrhosis in 10.1% of patients (96.3% positive predictive value), while ASPRI <5 excluded cirrhosis in 34.7% (100% negative predictive value).

Conclusions:

  • ASPRI is an accurate noninvasive biomarker for predicting liver cirrhosis in CHB patients.
  • Screening CHB patients with ASPRI has the potential to significantly reduce the number of liver biopsies required.
  • ASPRI offers a promising tool for risk stratification and clinical decision-making in CHB management.
Abstract

Related Concept Videos

Cirrhosis I: Introduction01:23

Cirrhosis I: Introduction

Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Cirrhosis II: Pathophysiology01:24

Cirrhosis II: Pathophysiology

Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...
Ultrasound II: Endoscopic Ultrasound and FibroScan01:25

Ultrasound II: Endoscopic Ultrasound and FibroScan

Endoscopic Ultrasound (EUS) and FibroScan are valuable diagnostic tools in gastroenterology and hepatology, each with specific applications and techniques.
Endoscopic Ultrasound (EUS):